Skip to main content

Understanding Tumor Heterogeneity and Altered Metabolism in Gliomas

Cover image for Research Topic "Understanding Tumor Heterogeneity and Altered Metabolism in Gliomas"
101kviews
ORIGINAL RESEARCH
25 August 2022
Based on clinical Ki-67 expression and serum infiltrating lymphocytes related nomogram for predicting the diagnosis of glioma-grading
Zhi Zhang, 9 more and Feng Qiu

2,750 views

7 citations

ORIGINAL RESEARCH
24 November 2021
Epidemiologic Features, Survival, and Prognostic Factors Among Patients With Different Histologic Variants of Glioblastoma: Analysis of a Nationwide Database
Li-Tsun Shieh, 4 more and Sheng-Yow Ho

6,313 views

17 citations

ORIGINAL RESEARCH
2 November 2021
SPAG5 Is Involved in Human Gliomagenesis Through the Regulation of Cell Proliferation and Apoptosis
Chunhong Wang, 2 more and Hongming Ji

3,198 views

11 citations

ORIGINAL RESEARCH
8 July 2021
Expression of TCF7L2 in Glioma and Its Relationship With Clinicopathological Characteristics and Patient Overall Survival
Shiyuan Jing, 5 more and Changxiang Yan

2,866 views

11 citations

ORIGINAL RESEARCH
6 July 2021
Development of a Prognostic Five-Gene Signature for Diffuse Lower-Grade Glioma Patients
Qiang Zhang, 6 more and Zhilin Su

2,726 views

5 citations

Differential Predictors and Clinical Implications Associated With Long-Term Survivors in IDH Wildtype and Mutant Glioblastoma
Background: Glioblastoma (GBM) is the most aggressive intracranial tumor which can be divided into two subtypes based on status of isocitrate dehydrogenase (IDH). A small fraction of patients after receiving standard treatment can be long-term survivors (LTS). This study was designed to disclose the predictors and clinical implications associated with LTS in IDH wildtype and mutant GBM. Methods: Patients who survived beyond five years after diagnosis of GBM were defined as LTS, while those with a survival less than one year were defined as short-term survivors (STS). A total of 211 patients with diagnosis of GBM in Beijing Tiantan Hospital from January 2007 to January 2015 were enrolled, including 44 (20.9%) LTS and 167 (79.1%) STS. The clinical, radiological and molecular features between groups were systematically compared. Results: Compared with STS, LTS were a subgroup of patients with a younger age at diagnosis (P=0.006), a higher KPS score (P=0.011), higher rates of cystic change (P=0.037), O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation (P=0.007), and IDH mutation (P=0.049), and more likely to have undergone gross total resection (P<0.001). Survival analysis demonstrated that LTS with wildtype IDH conferred a longer progression-free survival (66.0 vs. 27.0 months, P=0.04), but a shorter post-progression survival (46.5 months vs. not reached, P=0.0001) than those of LTS with mutant IDH. LTS with mutant IDH showed a trend towards increased survival after receiving re-operation (P=0.155) and reirradiation (P=0.127), while this clinical benefit disappeared in the subset of LTS with wildtype IDH (P>0.05). Conclusion: The prognostic value and therapeutic implications associated with LTS in GBM population significantly differed on the basis of IDH status. Our findings provide a new approach for physicians to better understand the two subtypes of GBM, which may assist in making more tailored treatment decisions for patients.

5,500 views

17 citations

CASE REPORT
20 May 2021
Primary Intracranial Leiomyosarcoma Secondary to Glioblastoma: Case Report and Literature Review
Liyan Zhao, 4 more and Yunqian Li

3,027 views

7 citations

The Role of 2-Oxoglutarate Dependent Dioxygenases in Gliomas and Glioblastomas: A Review of Epigenetic Reprogramming and Hypoxic Response
Gliomas are a heterogeneous group of cancers that predominantly arise from glial cells in the brain, but may also arise from neural stem cells, encompassing low-grade glioma and high-grade glioblastoma. Whereas better diagnosis and new treatments have improved patient survival for many cancers, glioblastomas remain challenging with a highly unfavourable prognosis. This review discusses a super-family of enzymes, the 2-oxoglutarate dependent dioxygenase enzymes (2-OGDD) that control numerous processes including epigenetic modifications and oxygen sensing, and considers their many roles in the pathology of gliomas. We specifically describe in more detail the DNA and histone demethylases, and the hypoxia-inducible factor hydroxylases in the context of glioma, and discuss the substrate and cofactor requirements of the 2-OGDD enzymes. Better understanding of how these enzymes contribute to gliomas could lead to the development of new treatment strategies.

15,136 views

27 citations

ORIGINAL RESEARCH
26 March 2021
Correlation Between APOBEC3B Expression and Clinical Characterization in Lower-Grade Gliomas
Hao Zhang, 7 more and Quan Cheng

4,804 views

20 citations

REVIEW
3 February 2021
Emerging Role of Long Non-Coding RNAs in the Pathobiology of Glioblastoma
Omidvar Rezaei, 3 more and Soudeh Ghafouri-Fard

7,201 views

48 citations